Insulin Degrading Enzyme Induces a Conformational Change in Varicella-Zoster Virus gE, and Enhances Virus Infectivity and Stability by Li, Qingxue et al.
Insulin Degrading Enzyme Induces a Conformational
Change in Varicella-Zoster Virus gE, and Enhances Virus
Infectivity and Stability
Qingxue Li
1, Mir A. Ali
1, Kening Wang
1, Dean Sayre
1, Frederick G. Hamel
2, Elizabeth R. Fischer
3, Robert G.
Bennett
2, Jeffrey I. Cohen
1*
1Laboratory of Clinical Infectious Diseases, National Institutes of Health, Bethesda, Maryland, United States of America, 2Research Service, Omaha VA Medical Center and
the Department of Internal Medicine, University of Nebraska Medical Center, Omaha, Nebraska, United States of America, 3Research Technology Branch, Rocky Mountain
Laboratories, National Institutes of Health, Hamilton, Montana, United States of America
Abstract
Varicella-zoster virus (VZV) glycoprotein E (gE) is essential for virus infectivity and binds to a cellular receptor, insulin-
degrading enzyme (IDE), through its unique amino terminal extracellular domain. Previous work has shown IDE plays an
important role in VZV infection and virus cell-to-cell spread, which is the sole route for VZV spread in vitro. Here we report
that a recombinant soluble IDE (rIDE) enhances VZV infectivity at an early step of infection associated with an increase in
virus internalization, and increases cell-to-cell spread. VZV mutants lacking the IDE binding domain of gE were impaired for
syncytia formation and membrane fusion. Pre-treatment of cell-free VZV with rIDE markedly enhanced the stability of the
virus over a range of conditions. rIDE interacted with gE to elicit a conformational change in gE and rendered it more
susceptible to proteolysis. Co-incubation of rIDE with gE modified the size of gE. We propose that the conformational
change in gE elicited by IDE enhances infectivity and stability of the virus and leads to increased fusogenicity during VZV
infection. The ability of rIDE to enhance infectivity of cell-free VZV over a wide range of incubation times and temperatures
suggests that rIDE may be useful for increasing the stability of varicella or zoster vaccines.
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Introduction
Varicella-zoster virus (VZV), a member of the alpha-herpesvirus
family, is the etiologic agent of chickenpox and shingles. In
humans, cell-free virions are released from skin lesions and are
transmitted to epithelial cells in the respiratory tract of susceptible
hosts [1]. In cell culture, however, no cell-free infectious virions are
spontaneously released, and infection is exclusively by cell-to-cell
spread of virus. While cell-free virus can be obtained by sonication
of infected cells, the lack of high titer cell-free virus has hindered
the progress of studies to define the mechanism by which VZV
enters into target cells.
Previous studies have identified cellular molecules that are
important for entry of VZV into cells. Cation-independent mannose
6-phosphate receptor (MPR
ci) has been proposed to facilitate an early
step of VZV infection [2]. Previous studies from our laboratory
showed that insulin-degrading enzyme (IDE), a member of the zinc
metalloproteinase family, is a putative cellular receptor for VZV [3].
Down-regulation of IDE by specific siRNA, inhibition of IDE activity
with bacitracin, or blocking IDE with antibody inhibited VZV
infection and impaired cell-to-cell spread of the virus. Over-
expression of human IDE by transfection into cell lines resulted in
increased entry of both cell-free and cell-associated virus. VZV
glycoprotein E (gE), which is essential for virus infectivity [4,5],
interacts with IDE through a binding domain located at the amino
terminus of the ectodomain of gE that is not conserved in other
human herpesviruses [3,6,7,8]. VZV deleted for the IDE binding
domain in gE is impaired for infectivity of cell-free virus [5] and shows
reduced cell-to-cell spread of virus both in vitro and in human skin
xenografts in SCID mice [5,8]. Here, we show that the interaction of
IDE with gE is important for VZV-induced syncytia formation and
fusogenicity, and that recombinant soluble IDE (rIDE) modifies gE,
induces a conformation change in gE, enhances VZV infectivity, and
stabilizes cell-free virus.
Results
rIDE augments cell-free VZV infectivity at an early stage
of infection and enhances stability of cell-free virus
The open reading frame of human IDE contains two ATGs
near the amino terminus that could serve as translation initiation
codons. Previous studies with cloned IDE cDNA showed that the
second ATG encoding amino acid 42, which better matches a
Kozak consensus sequence, serves as the canonical start site for
translation [9,10]. Recombinant baculovirus was constructed to
express human IDE with a hemaglutinin (HA) tag inserted after
the second methionine (amino acid 42) of IDE driven by
polyhedrin promoter [3,11] (Fig. 1A). rIDE was expressed as a
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merization of the protein as has been reported previously [12].
Incubation of rIDE with radiolabeled insulin resulted in a similar
profile of degradation products as seen with endogenous IDE from
rat liver [13] or another form of recombinant IDE [14] (Fig. 1C).
rIDE had insulin degrading activity similar to recombinant
6HisFlag-IDE (Fig. 1D).
Previously we showed that IDE interacts with the extracellular
domain of VZV gE, that a gE mutant lacking amino acids 32–71
cannot bind IDE, and that a gE mutant lacking amino acids 163–
208 is unable to bind to VZV gI and shows enhanced binding to
IDE [6]. Here we found that rIDE also formed a complex with the
extracellular domain of gE, that rIDE did not interact with gE
lacking the IDE binding domain, and that rIDE interacted to a
greater extent with the mutant gE that does not bind gI (Fig. 1E).
Previously, we reported that purified endogenous IDE protein
extracted from liver blocked VZV infection, while rIDE from
cloned cDNA expressed in baculovirus-infected cells enhanced
VZV infectivity [3]. The difference in the activity of these two
proteins could be due to the difference in their amino termini.
rIDE begins at a canonical initiation codon at amino acid 42.
Purified rIDE showed a single band of 110 kD while native IDE
purified from liver is actually a complex mixture of IDE forms. To
further investigate the effect of rIDE on VZV infectivity, we
incubated cell-free VZV ROka-lacZ with rIDE or control proteins
for 15 min at 37uC before infecting human melanoma cells with
the virus. Three days later, the cells were fixed and treated with X-
gal and blue foci were counted. rIDE significantly enhanced VZV
infectivity compared with control protein or SPGC buffer alone
(P,0.001 for rIDE vs. control protein, Student t test, Fig. 2A).
Enhancement of infectivity was not observed when rIDE was
added at 4 hr post-infection which bypasses the entry step
(P,0.0001 for rIDE added at 15 min before infection vs. rIDE
added 4 hr after infection by Student t test, Fig. 2A). Denaturation
of rIDE with 12.5 mM citric acid at pH 2.3 followed by
neutralization with 0.5 M HEPES buffer at pH 9.0 to a final
pH 7.0, inactivated the enhancing activity of IDE. These results
indicate that the native form of rIDE is required to enhance
infectivity and that rIDE functions at an early stage of infection.
Incubation of rIDE with cell-free VZV at 37uC for 15 min before
adding the virus to cells enhanced infectivity in a dose-dependent
manner (P=0.0002 by ANOVA) (Fig. 2B).
Since VZV is highly cell-associated in vitro, and cell-free virus
produced by sonication is very labile and its infectivity declines
Figure 1. rIDE is expressed in insect cells, degrades insulin, and binds to VZV gE. (A) Structure of HA-tagged rIDE and its promoter in
recombinant baculovirus. (B) rIDE was purified, eluted under native conditions, and stained with Coomassie Blue. Soluble rIDE is expressed as a
110 kDa protein in insect cells. (C) HPLC profiles of insulin degradation fragments observed after co-incubation of radiolabeled insulin with rIDE
expressed in insect cells, endogenous IDE extracted from rat liver (top panel), or recombinant IDE (6His/Flag-IDE) expressed in eukaryotic cells
(bottom panel). (D) Insulin-degrading enzymatic activities of IDE proteins. (E) ELISA assay for binding of rIDE to gEt, gEt lacking the IDE binding
domain (gEtD32-71), gEt defective in binding to VZV gI (gEtD163-208), and a negative control protein (P7.5, vaccinia 7.5 protein). The horizontal
dotted line indicates the level of nonspecific binding based on the control protein.
doi:10.1371/journal.pone.0011327.g001
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with rIDE enhances stability of the virus. rIDE increased virus
infectivity when incubated with cell-free ROka-lacZ for 1 or 3 hr
at 37uC compared with buffer or with filtrate passing through the
rIDE purification (Fig. 2C). rIDE also enhanced cell-free VZV
infectivity and/or stability after incubation for 18 hrs at 25uC
prior to infecting cells (P=0.002 for rIDE vs. buffer or controls,
Student t test) (Fig. 2A last two columns and Fig. 2D).
Enhancement of virus stability by incubating rIDE with VZV
was observed over a range of incubation periods at room
temperature (Fig. 3A, P=0.0002 for rIDE vs. BSA control for
combined data from 11 experiments (each with $2 replicates).
Incubation of rIDE and cell-free virus at 4uC for 60 min before
infection of cells also augmented VZV infectivity (Fig. 3B). These
results indicate that rIDE enhances both infectivity and stability of
cell-free VZV over a wide range of incubation times and
incubation temperatures.
To further determine if the effect of rIDE on VZV infectivity is
at an early step of virus infection, we performed quantitative PCR
for VZV DNA to determine the copy number of viral genomes
inside the cells 90 min after infection. Incubation of rIDE with
virus prior to infection resulted in increased numbers of VZV
genomes inside the cells, compared with virus incubated with a
control protein, indicating that rIDE increases virus internalization
(P,0.0001 for rIDE vs. P7.5, Fig. 4A). Addition of rIDE at 2.5 hr
after infection with VZV resulted in an increase in the size of
Figure 2. rIDE enhances VZV infectivity at an early stage of infection and increases the stability of virus. (A) Cell-free VZV (ROka-LacZ)
virus was pre-treated with buffer, bovine serum albumin (BSA), rIDE (15 mg/ml), or denatured rIDE (IDE treated with acid and then base to a final
neutral pH) at 37uC for 15 min before infecting melanoma cells. Infected cells were stained with X-gal at 3 days after infection to identify the number
of VZV-positive foci. The experiment was repeated 10 times and a representative experiment is shown. For the 5
th bar, cells were infected with the
same amount of virus as in bars 1-4, and rIDE was then added to the cells 4 hours post-infection. For the last two bars, the virus was incubated with
rIDE or buffer at 37uC for 15 min and kept at 25uC for 18 hrs before infecting MeWo cells. (B) Cell-free ROka-LacZ was pre-incubated with increasing
concentrations of rIDE (shown in mg/ml) at 37uC for 15 min and infected cells were stained with X-gal. The experiment was performed twice and one
result is shown. The control proteins, P7.5 and BZLF2, were used at a concentration of 20 mg/ml. (C) Cell-free VZV (ROka-LacZ) was pre-incubated with
rIDE, buffer, or filtrate passing through the rIDE purification column under the indicated conditions and infected cells were stained with X-gal at 4
days post-infection. The filtrate (control) consists of HA peptide which was used to elute rIDE from the purification column. (D) Cell-free ROka-LacZ
virus was incubated with buffer, bovine serum albumen (BSA), filtrate that passed through without binding to a rIDE purification column, or rIDE for
18 hrs at 25uC before infecting cells and staining with X-gal. The experiment was performed 3 times, and a representative result is shown.
doi:10.1371/journal.pone.0011327.g002
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Buffer, Fig. 4B), suggesting that rIDE not only augments infectivity
of cell-free virus at entry but also promotes infectivity through
enhanced cell-to-cell spread of virus. This is consistent with our
earlier observation that IDE is important for infection with both
cell-free and cell-associated VZV [3].
Figure 3. rIDE enhances VZV infectivity and increases the stability of virus. (A) Cell-free ROka-LacZ was pre-incubated with rIDE or BSA at
25uC for the indicated time before infecting MeWo cells. The ratio of the number of blue foci in cells infected with virus treated with rIDE or
BSA(control) was determined. The experiment was preformed 11 times and a representative experiment is shown. Vertical lines indicate standard
deviations. (B) Pre-treatment of VZV with rIDE at 4uC enhances viral infectivity. Cell-free ROka-GFP virus was incubated with medium, BSA, rIDE or
denatured rIDE (rIDE treated with acid followed by base to a final neutral pH) for 60 min at 4uC before infecting cells. (P=0.001 for rIDE vs. denatured
rIDE, Student t test). Vertical lines indicate standard deviations. The experiment was performed 3 times, and a representative result is shown.
doi:10.1371/journal.pone.0011327.g003
Figure 4. rIDE promotes VZV internalization during entry and cell-to-cell spread of virus. (A) Cell free ROka-lacZ was incubated with P7.5
control protein or rIDE for 30 min at 37uC, the mixture was incubated with cells for 60 min on ice to allow binding followed by 90 min at 37uC for
entry, and DNA was then extracted from the cells and the copy number of intracellular VZV genomes was determined by real-time PCR. The ratio of
VZV ORF 62 DNA to cellular RNaseP DNA is shown on the y axis. The experiment was performed three times and a representative result is shown. (B)
Melanoma cells were infected with ROka-lacZ, 2.5 hrs later the inoculum was removed by washing with PBS, rIDE was added to the cells, and 3 days
later the cells were stained with X-gal. Blue VZV-infected foci were photographed at a magnification 40X and plaque sizes were measured with
ImageJ software as previously described [3]. N is the number of plaques measured. (C) Cell-free VZV from a commercial lot of zoster vaccine was
incubated with rIDE for 30 min, melanoma cells were infected with the mixture for 4 days, and the cells were fixed and stained with anti-gE
monoclonal antibody and infected foci were visualized by fluorescence microscopy. The graph represents pooled data from three independent
experiments. Vertical lines indicate standard deviations.
doi:10.1371/journal.pone.0011327.g004
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recombinant-derived VZV, we also tested the effect of rIDE on
non-recombinant viruses. Cell-free zoster vaccine virus, which
contains various stabilizers, was reconstituted according to the
manufacturer’s instruction, and incubated with rIDE or control
proteins for 30 min at 37uC. rIDE increased the infectivity of
zoster vaccine virus (P,0.0001 for rIDE vs. buffer, bovine serum
albumen (BSA), or P7.5 control protein by Student t test; Fig. 4C).
rIDE modifies VZV gE and induces a conformational
change in gE
IDE is a metalloproteinase. While IDE interacts with a variety
of substrates, it cleaves only a subset of its substrates such as insulin
and b-amyloid protein at perceptible rates [15,16]. Previously, we
incubated the extracellular domain of gE (gEt) with IDE protein
extracted from liver and did not detect cleavage or degradation of
gEt using a monoclonal antibody [3]. To determine if rIDE
modifies gE, we incubated biotin-labeled gEt protein with rIDE or
control proteins (P7.5-Fc which encodes vaccinia virus P7.5
protein or BZLF2-Fc which encodes Epstein-Barr virus BZLF2
protein) at 37uC, 22uC, or 4uC for 30 min. The proteins were then
boiled in sample buffer, separated on an SDS-PAGE gel, and gEt
was stained with streptavidin conjugated-horse radish peroxidase.
Incubation of gEt with rIDE, but not with the control proteins,
resulted in a slightly smaller sized band than full length gEt,
indicating that rIDE modifies gEt (Fig. 5A). While it was somewhat
surprising that rIDE modified gE after incubation at 4uC, this is
consistent with our observations that rIDE enhanced VZV
infectivity at 4uC (Fig. 3B).
Many viral glycoproteins undergo conformational changes after
binding their receptor or co-receptor which results in the exposure of
fusion peptides embedded in the viral glycoproteins that initiate a
series of events leading to fusion between the viral envelope and the
cell membrane [17,18]. Since VZV gE has an important role in
syncytia formation and membrane fusion [19], we postulated that gE
might undergo a conformational change after binding to rIDE.
Limited exposure of ligand-receptor complexes to proteinase has
been used to detect receptor-induced conformational changes in
several proteins, including avian sarcoma/leucosis virus (ALV)
envelope protein complexed with its receptor Tva and spike protein
of mouse hepatitis virus complexed with soluble receptor, CEA-
CAM1a [20,21,22]. The extracellular domain of gE was labeled with
Figure 5. rIDE modifies gEt and induces a conformational change in gEt. (A) Biotin labeled gEt-Fc protein (arrow) was incubated with rIDE at
the indicated temperature for 30 min. After electrophoresis and transfer onto a nitrocellulose membrane, proteins were visualized with streptavidin-
conjugated-horse radish peroxidase. (B) Biotin-labeled gEt-His protein (arrow) was incubated with buffer, control protein BZLF2 or P7.5, rIDE
(produced in baculovirus) at 37uC for 30 min, followed by urea for 18 hr and thermolysin for 30 sec. The proteins were separated by electropheresis,
transferred to a nitrocellulose membrane and proteins were detected using streptavidin-conjugated horse radish peroxidase. (C) Biotin-labeled gEt-
His protein (arrow) was incubated with rIDE or control proteins at 37uC for 30 min, followed by incubation with 4 mg/ml of endoproteinase Asp-N
(Roche Applied Science, Indianapolis, IN) at 37uC for 45 sec. The digestion was then terminated by adding 0.5 M EDTA and samples were boiled in
SDS-PAGE gel loading buffer with 2.5% 2-mercaptoethanol and separated by electrophoresis. Protein fragments were detected by streptavidin
conjugated-horse radish peroxidase. (D) Binding of catalytically inactive IDE mutant protein IDE-E111Q to gEt fails to induce a conformational change
in gE. Biotin-labeled gEt-His protein (arrow) was incubated with rIDE (produced by baculovirus), IDE-E111Q (produced in bacteria), or IDE-w. t.
(produced in bacteria), or negative control proteins as indicated at 37uC for 30 min, followed by thermolysin and processed as described in panel B.
(E) Coomassie Blue stained SDS-PAGE gel showing the amount of IDE-E111Q and IDE-w.t. proteins used for pulse proteolysis assay in panel D.
doi:10.1371/journal.pone.0011327.g005
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room temperature for 30 min followed by addition of thermolysin, a
proteinase that hydrolyzes peptide bonds at hydrophobic residues, for
30 sec. Proteins were separated on an SDS-PAGE gel and incubated
with streptavidin conjugated-horse radish peroxidase. Incubation of
gEt with rIDE, but not with buffer or control protein, resulted in a
reduction in the intensity of the 70 kDa gEt band (Fig. 5B and 5D).
Similar results were also observed with endoproteinase Asp-N
digestion (Fig. 5C). Therefore, rIDE triggered a conformational
change in VZV gEt that confers an increased susceptibility to
proteinase. Repeated attempts to determine a cleavage site on gE by
N-terminal protein sequencing failed to generate any sequences.
Glutamic acid 111 in the zinc-binding site of human IDE is a
major catalytic residue for its insulin degrading function [23].
Mutation of glutamic acid 111 to glutamine in IDE results in a
mutant protein, IDE-E111Q, which is catalytically inactive for
insulin degradation. Although IDE-E111Q formed a complex with
gEt (Fig. 6), it failed to elicit a conformational change in gEt as
compared with rIDE or wild-type IDE in the thermolysin assay
(Fig. 5D, E). These results suggest that the catalytic activity of IDE
for insulin degradation might be important for inducing a
conformational change in gE.
A VZV mutant lacking the IDE binding domain of gE is
impaired for membrane fusion and syncytia formation
To determine if the interaction of gE with IDE is important for
membrane fusion, we used a reporter system in which VZV
permissive HeLa cells were transfected with a plasmid encoding b-
galactosidase under the T7 promoter (pG1N-T7-b-gal) and served
as target cells. One day after transfection, the target cells were
incubated for 20 hr with melanoma cells stably expressing T7
polymerase that contained equal titers (10
5 PFU/ml) of control
VZV (ROka) or a mutant virus, ROka68D32-71 that lacks the
IDE binding domain (amino acids 32 to 71) of gE. Incubation of
target cells with ROka68D32-71-infected cells resulted in reduced
membrane fusion activity as measured by lower levels of b-
galactosidase compared with ROka-infected cells (P=0.0001 for
ROka vs. ROka68D32-71 by Student t test; Fig. 7A). Similar
results were observed with ROka68D32-71-GFP (which also
expresses GFP) and ROka-GFP (Fig. 7B). Transfection of HeLa
cells with vector control plasmid, in place of the reporter plasmid,
followed by infection with VZV ROka resulted in a background
level of fusion activity. Therefore, VZV mutants lacking the IDE
binding domain of gE have reduced membrane fusogenicity.
To further examine the function of IDE in VZV infection, we
analyzed syncyctia formation in cells infected with ROka68D32-
71 and ROka68D32-71-GFP. While the truncated gE in
ROka68D32-71 virus is impaired for binding to IDE in a pull-
down assay, the mutant virus is not impaired for maturation and
egress to the cell surface [5]. Both ROka68D32-71 and
ROka68D32-71-GFP showed smaller syncytia with fewer nuclei
in the syncytia compared with their parental viruses, ROka or
ROka-GFP (Fig. 8A and B). Cells infected with ROka68D32-71-
GFP had significantly fewer nuclei per syncytium than cells
infected with ROka-GFP when the total number of nuclei in
syncytia were quantified using 3 dimensional reconstruction of
sequential Z-sections of cells with confocal microscopy (Fig. 8C,
p,0.001).
A VZV mutant lacking the IDE binding domain of gE
accumulates on the cell surface or the cell-cell junction
To rule out the possibility that the reduced level of syncytia
formation of the VZV mutant might be due to defective
maturation and transport to cell surface and/or to cell-cell
junctions, we performed immuno-electron microscopy studies.
Melanoma cells infected with ROka68D32-71 showed large
numbers of enveloped virions accumulating at cell-cell junctions
(Fig. 9A) and on the cell surface (Fig. 9B). In 53 randomly selected
immune-electron micrographs, there were a total of 873 gE-
positive ROka68D32-71 virions on the cell surface and/or in cell
junctions, compared with a total 140 gE-positive ROka virions in
41 pictures (Fig. 9C, P,0.00001 for ROka68D32-71 vs. ROka),
indicating that the impairment in syncytia formation and cell-to-
cell spread of the IDE binding domain mutant virus is not due to
defective maturation with reduced transport to the cell surface or
to cell-cell junctions. A previous study showed that VZV gE is
myristylated [24]. Myristylation of proteins is important for their
association with membranes. To rule out the possibility that
deletion of the IDE binding domain of gE does not adversely affect
gE myristylation, we labeled ROka or ROka68D32-71 infected
cells with
3H-myristic acid and immunoprecipitated gE. gE from
both parental and mutant VZV showed similar levels of
myristylation, indicating that differences in myristylation do not
explain the phenotype observed with the mutant virus (Fig. 10).
Therefore, the IDE binding domain of gE is important for
membrane fusogenicity, syncytia formation, and for cell-to-cell
spread of the virus.
Discussion
We have shown that soluble rIDE enhances VZV infectivity and
cell-to-cell spread in human melanoma cells at an early step of
virus infection. rIDE interacted with gE to elicit a conformational
change in gE and modified the size of gE. In addition, a VZV
mutant virus lacking the IDE binding domain of gE was impaired
for syncytia formation and membrane fusion, suggesting that IDE
enhances infectivity and stability of the virus through eliciting a
conformational change in gE and modulating fusogenicity during
VZV infection.
Figure 6. IDE mutant protein, IDE-E111Q binds to gEt. gEt but
not control protein p7.5, pulled down both IDE-E111Q protein and wild-
type IDE (arrow).
doi:10.1371/journal.pone.0011327.g006
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that IDE functions as a cellular receptor for gE enhancing VZV
infectivity and cell-to-cell spread in these two cell types [3,5].
However, a recent study found that although a VZV mutant with
a deletion in the IDE binding domain of gE showed reduced cell-
to-cell spread of virus in melanoma cells and impaired infectivity of
Figure 7. VZV mutant lacking the IDE binding domain of gE shows reduced fusogenicity by membrane fusion assay. (A) Melanoma
cells expressing T7 polymerase were infected with VZV ROka, ROka68D32-71, and the cells were incubated with HeLa cells containing the b–
galactosidase gene driven by the T7 promoter or a control GFP plasmid for 20 hr. The cells were lysed, incubated with chlorophenol red-b-D-
galactopyranoside, and b–galactosidase activity was measured using a spectrophotometer at OD570 nm. The experiment was also performed at
16 hr and 24 hr and similar results were obtained. Vertical lines indicate standard deviations. (B) Human melanoma cells expressing T7 polymerase
were infected with the same MOI of ROka-GFP or ROka68D32-71-GFP, and cells were co-incubated with HeLa cells containing the b–galactosidase
gene driven by the T7 promoter for 16 hrs. The cells were lysed, incubated with chlorophenol red-b-D-galactopyranoside, and b–galactosidase
activity was measured using a spectrophotometer at OD570 nm. The experiment was performed twice with similar results. (P,0.001 for ROka-GFP vs.
ROka68D32-71-GFP, Student t test). Vertical lines indicate standard deviations.
doi:10.1371/journal.pone.0011327.g007
Figure 8. VZV mutants deleted for the IDE binding domain of gE are impaired for syncytia formation. (A) Melanoma cells were infected
with VZV ROka or ROka68D32-71 and stained with DAPI (top panels) or mouse monoclonal antibody to gE followed by anti-mouse-Alexa-488 and
visualized by immunofluorescence microscopy. Magnification 40X. (B) Melanoma cells were infected with VZV ROka-GFP or ROka68D32-71-GFP and
visualized directly by fluorescence microscopy. Magnification 40X. (C) Quantification of the number of nuclei in syncytia per nucleus was performed
using confocal microscopy (Leica SP2, Leica Microsystems, Exton, PA). Sequential Z-sections of DAPI stained infected cells were acquired for 3D
reconstruction of representative cells with Imaris software (version 6.2, Bitplane AG, Zurich, Switzerland). The numbers of nuclei were automatically
determined using spot function in Imaris software and manually corrected for errors by independent investigators in Biological Imaging, Research
Technologies Branch, NIH. Vertical lines show standard deviations. n represents the number of syncytia analyzed in which nuclei were counted by a
microscopist who was unaware of the expected outcome of the experiment.
doi:10.1371/journal.pone.0011327.g008
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suggesting that IDE may facilitate virus entry in a cell-type
dependent manner, similar to gp42 of Epstein-Barr virus [25]. For
the closely related herpes simplex virus (HSV), cellular molecules
have also been shown to preferentially mediate virus entry in
different cell types; nectin-1 is important for entry of HSV in
neurons, while HVEM is used for entry in lymphocytes [26].
VZV gE binds to IDE through its amino-terminal region,
although the overall conformation of gE is important for its
interaction with IDE [6,8]. The observation that gE produced by
the baculovirus expression system is smaller in size than its
counterpart produced from mammalian cells (Li et al., unpub-
lished data) suggests that it is less glycosylated in insect cells. gE
produced by baculovirus forms a complex with IDE [3], which
implies that glycosylation of gE may not be important for
interaction with IDE. Carpenter et. al. reported that IDE binds
to the mature 98-kDa form of VZV gE under low salt conditions,
but IDE binds only to the 73 kDa form of gE at high salt
conditions [27]. They showed that tunicamycin blocks glycosyl-
ation of gE in the endoplasmic reticulum resulting in only
production of the 73 kDa form of gE, and that in the presence of
tunicamycin, gE was blocked in its transit out of the endoplasmic
reticulum. Therefore they concluded that IDE must interact only
with the 73 kDa form of gE in the cytosol and that this binding
does not represent a receptor/ligand interaction. Interestingly, a
previous study by these authors showed that the smaller form of gE
is present on cell surface, recycles through the endocytotic
pathway, and is incorporated into virions [28]. Studies from other
groups also showed that a mixture of forms of gE ranging from
,50–100 kDa are present in purified virions [29,30,31]. There-
fore, the 73 kDa form of gE is present in virions where it may
interact with IDE.
Soluble receptor-mediated enhancement of virus infectivity has
been reported for several viruses including HIV, avian leukosis/
sarcoma virus, mouse coronavirus, [32,33,34,35] and the closely
related herpes simplex virus (HSV). Nectin-1 and 3-O-sulfated
heparan sulfate function as receptors for HSV [36,37]. Soluble 3-
O-sulfated heparin sulfate triggers HSV entry into non-permissive
cells and augments viral glycoprotein-mediated membrane fusion
[38]. A soluble truncated form of nectin-1 lacking the transmem-
brane domain confers HSV susceptibility to non-permissive cells
[39]. Further studies showed that the soluble V domain of nectin-
1, (amino acid residues 1–123), promotes HSV entry. Interestingly,
in this study neither free nor gD-bound sNec1123 was bound to the
cell surface, suggesting that the interaction of soluble receptor with
its gD ligand facilitates virus penetration by activating viral fusion
Figure 9. Accumulation of a VZV mutant deleted for the IDE binding domain of gE at the cell surface and at the cell-cell junction.
Melanoma cells were infected with VZV ROka or ROka68D32-71, fixed, and incubated with monoclonal antibody to VZV gE followed by
FluoroNanogold-conjugated anti-mouse antibody and visualized by transmission electron microscopy. (A) Representative virions at cell-cell junctions
are indicated with arrows. Magnification 120006. The insets in panel A provide higher-power images of selected virions. (B) Representative virions on
the cell surface are indicated with arrows. Magnification 50006. (C) Quantification of gE-positive virions on the cell surface and at cell-cell junctions.
Multiple cells from the experiment in panel A were coded and observed under a Hitachi H7500 transmission electron microscope. gE positive viral
particles at cell surface and/or junctions were counted.
doi:10.1371/journal.pone.0011327.g009
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[40]. While rIDE increased VZV infectivity at an early stage of
infection, treatment of radiolabeled VZV with rIDE did not
enhance virus binding (Fig. 11). Thus, soluble rIDE appears to
promote VZV infectivity by increasing the efficiency of entry of
virus into cells, rather than enhancing attachment. This conclusion
is further supported by the observation that rIDE increases
internalization of VZV DNA within 90 min of initiating infection.
We found that rIDE induces a conformational change in VZV
gE. Numerous studies have established that receptor binding-
induced conformational change in viral glycoproteins is critical in
initiating virus-mediated membrane fusion. The conformational
change results in exposed viral fusion peptides and provides energy
for the fusion process through refolding [18,41,42]. For larger
viruses such as HSV, the fusion machinery consists of more than
one glycoprotein working in concert [43,44]. Since VZV gE is not
fusogenic when expressed alone, but does act as a fusogen in
concert with other glycoproteins [45], it is possible that the
conformational changes elicited by rIDE may either directly
enhance fusogenicity of gE, or allow recruitment of glycoproteins
gB and gH, to form a fusion complex.
In addition to the receptor-binding mediated conformational
change of viral glycoprotein, sequential conformational changes
induced by proteolysis are required during the entry process of
several viruses. Proteases cleave viral fusion proteins, including
glycoproteins, into mature, fusogenic forms and enhance virus
binding and infectivity [46,47,48,49,50,51,52,53]. Our finding that
rIDE, a metalloproteinase, triggers a conformational change in gE
and modifies the size of gE suggests that a proteolytic activity of IDE
might beimportant forVZVinfectivity.Thisisfurther supported by
the fact that the IDE mutant (IDE-E111Q) which is impaired for
degradation of insulin, fails to induce a conformational change in
gE.Since gE is muchlargerthan insulin and gE lacks anydetectable
amino acid homology with other substrates of IDE, the interacting
amino acid residues of IDE with insulin and gE are likely to be
different. Therefore, there may be a proteolytic motif of IDE for gE
which is different from that for degrading insulin.
HSV enters cells through different pathways involving either the
cell surface membrane or intracellular vesicles such as endosomes
in a cell-type dependent manner [26,54,55]. Previous work by
Hambleton and colleagues suggested VZV enters human
fibroblasts through an endocytosis pathway [56]. Although we
have shown that rIDE enhances VZV internalization, it is not
clear whether this occurs at the cell surface or in endosomes. In
most cell types, endogenous IDE localizes primarily in endosomes
and other subcellular compartments with about 10% on the cell
surface or in extracellular spaces. It is interesting to note that upon
receptor binding, activation of coronavirus glycoprotein by
extracellular proteases facilitates virus entry through the cell
surface plasma membrane, while in the absence of extracellular
proteases the virus enters the cell using the endosomal pathway
[22].
We found that rIDE increased the stability of cell-free VZV.
There are two possible explanations for how rIDE might enhance
Figure 10. Deletion of IDE binding domain on gE (amino acids
32–71) does not affect myristylation of gE. ROka or ROka68D32-71
infected cells were radiolabeled with
3H-myristic acid and immunopre-
cipitated with anti-gE antibody.
doi:10.1371/journal.pone.0011327.g010
Figure 11. Treatment of VZV with rIDE does not increase virus
binding. POka (parental Oka VZV) or mock infected MRC-5 cells were
metabolically labeled with
3H-thymidine at 0.25 mCi/ml for 36 hr
beginning at 8 hr post-infection, and cell-free virus was prepared by
sonication as described above. The virus was then pre-incubated with
rIDE or control proteins at 37uC for 30 min before addition to human
melanoma cells on ice for 80 min in the presence of 100 mg/ml of
heparin (to block binding through cell surface heparin sulfate). After
extensive washing with cold PBS, the cells were lysed and radioactivity
bound to cells was measured. The number of radioactive counts per
minute for mock-infected MRC-5 cells was subtracted from the counts
per minute for POka-infected cells (P=0.1 for rIDE vs. BSA or for rIDE vs.
BZLF2, Student t test). The data shown are based on two independent
experiments.
doi:10.1371/journal.pone.0011327.g011
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receptor may convert the glycoprotein from its native state to a
new metastable state resulting in a long-lived envelope protein-
receptor intermediate. ALV pre-loaded with a form of soluble
receptor, Tva/Tvb, is very stable at 37uC [57]. Second, pre-
treatment of virus with its receptor may target the virus to enter
cells through a pathway that is more favorable for infection. ALV
bound to the glycophosphatidylinositol-anchored form of its
receptor (Tva) accumulates in a fusion compartment where it is
more stable than if it enters though the transmembrane-anchored
form of the receptor [58]. Although endogenous IDE is found both
on the cell surface and in endosomes, it does not contain a
predicted membrane anchoring domain. It has been postulated,
however, that IDE might contain a glycophosphatidylinositol
anchor [59].
Cell-free VZV is usually produced in vitro by sonicating
infected cells and the virus is very labile. The current varicella and
zoster vaccines used in the United States are supplied as
lyophilized viruses that must be stored at 220uC or colder, and
used within 30 minutes after they are reconstituted in aqueous
solution [60]. rIDE might be useful as an additive for cell-free
VZV vaccines to improve their stability.
We found that VZV lacking the IDE binding domain of gE is
impaired for virus-induced membrane fusion, syncytia formation
and cell-to-cell spread, even though gE-positive virions accumulate
on the cell surface and at cell junctions. Transmission of VZV in
vitro occurs exclusively by cell-to-cell spread. Grose and colleagues
have postulated that VZV has evolved viral glycoproteins geared
more towards cell-to-cell fusion to mediate syncytia formation
rather than towards virus-to-cell fusion as seen in HSV [19].
Several studies suggest that gE has an important role in virus-
induced membrane fusion during infection [19,61]. gE promotes
fusion when co-expressed with either gB or gH in transfected cells
or using a vaccinia virus expression system [45,62]. Berarducci et
al. described a VZV mutant (rOka-P27-Y51) with a deletion in
part of the IDE binding domain of gE that shows reduced cell-to-
cell spread [7]. Our findings that a VZV mutant deleted for the
IDE binding domain is impaired for syncytia formation and
membrane fusion provides further evidence for the role of gE both
as a receptor binding molecule and as a contributor to
fusogenicity. We propose that the interaction of IDE with gE
results in receptor binding and a conformational change that may
include proteolysis. This process would lead to enhanced
fusogenicity either alone or in conjunction with the recruitment
of other viral glycoproteins during entry of VZV into target cells.
Materials and Methods
Cells and viruses
Human melanoma cells (MeWo [61], from Charles Grose,
University of Iowa) and fibroblast cells (MRC-5, American Type
Culture Collection, Manassas, VA) were grown in Minimum
Essential Medium with 10% fetal bovine serum (FBS). HeLa cells
(American Type Culture Collection) were maintained in Dulbec-
co’s Modified Eagle Medium with 10% FBS. SF9 or H5 (Spodoptera
frugiperda) insect cells were cultured in TNM-FH medium (BD
Biosciences Pharmingen, San Diego, CA).
VZV strains ROka (recombinant derived Oka), ROka-lacZ
(ROka expressing beta-galactosidase) [63], ROka-GFP [3], and
VZV mutant ROka68D32-71 [5] were grown on MeWo cells.
ROka68D32-71-GFP was constructed by inserting a cassette
containing the human cytomegalovirus promoter driving green
fluorescence protein (GFP) (from plasmid pEGFP-N1, Clontech-
BD Biosciences, Palo Alto, CA) into the AvrII site of cosmid VZV
MstIIA-68D32-71 located between VZV ORF65 and ORF66.
The resulting cosmid was tranfected into melanoma cells along
with plasmid pCMV62 and cosmids NotI A, Not IB, and Mst IIB,
and the virus obtained was termed ROka68D32-71-GFP.
Cell-free VZV virus was prepared from VZV-infected MRC-5
cells that displayed 50–80% cytopathic effects (CPE) by scraping
cells from flasks in SPGC buffer (10% FBS, 0.1% sodium
glutamine, 5% sucrose in PBS), freeze-thawing the cells once,
sonicating the lysate, centrifuging the lysate at 1,2406g for 10 min
at 4uC, and transferring the supernatant to a new tube as virus
stock. Cell-free zoster vaccine (Zostavax, Merck, Whitehouse
Station, NJ) was reconstituted in sterile water following the
manufacturer’s instructions and used for some experiments.
VZV infectivity assay
Cell-free VZV virus encoding b-galactosidase or GFP was
incubated with rIDE or other proteins and added to MeWo cells in
SPGC buffer at 33uC for 90 min before changing to normal
growth medium. Infected foci were scored at day 3–5 post-
infection by staining with 5-bromo-4-chloro-3-indolyl b-D-galac-
topyranoside (X-gal).
Cell-free vaccine virus was reconstituted in sterile water (as
recommended by the manufacturer) and added to MeWo cells as
described above. Four days after infection, the cells were fixed and
stained with anti-gE monoclonal antibody (Chemicon, Temecula,
CA) followed by anti-mouse-Alexa 488 secondary antibody
(Invitrogen, Carlsbad, CA) and infected foci were visualized by
fluorescence microscopy.
Construction of recombinant IDE and IDE mutants
Construction of recombinant baculovirus expressing HA-tagged
human IDE (rIDE) has been reported elsewhere [3] and was used
to infect SF9 or H5 insect cells. Three days post-infection the cells
were collected, treated with lysis buffer (25 mM Tris-HCl pH 7.4,
5 mM EDTA, 15 mM NaCl, and 0.1% NP40), and the lysate was
centrifuged at 2,450 g for 30 min at 4uC. HA-tagged rIDE was
purified from the cleared supernatant through an anti-HA
conjugated affinity column (Sigma, St. Louis, MO) at 4uC. After
extensive washing with PBS, rIDE was eluted with HA peptide
(200 mg/ml in PBS). Excess HA peptide was removed using a
Centriprep column with a 10 kDa molecular weight cut-off
(Millipore, Billerica, MA). For some experiments HA-IDE was
further purified through a gel filtration column in 25 mM Tris,
pH 8.0, 150 mM NaCl buffer.
Expression and purification of polyhistidine-tagged human wild-
type (IDE-w.t.) and mutant (IDE-E111Q) IDE proteins in E. coli
were performed as previously described [12] with minor
modifications. Briefly, plasmids pProEX-IDEwt and pProEX-
IDE-E111Q [12] were propagated in E. coli Rosetta (DE3) cells
and protein expression was induced with isopropyl-1-thiogalacto-
pyranoside at a final concentration of 200 mM for 16 hrs. The cells
were then lysed in RIPA buffer (10 mM Tris-HCl, pH 8.0,
100 mM NaCl, 1 mM EDTA, 0.1% NP40, 0.5% deoxycholic
acid, 0.5% SDS), and polyhistidine-tagged IDE was purified
through a Talon metal affinity column (Clontech, Mountain View,
CA), eluted with 250 mM imidazole, and dialyzed overnight in
PBS at 4uC.
Purification and biotinylation of gEt protein
Insect SF9 cells were infected with a recombinant baculovirus
expressing the extracellular domain of VZV gE with a C-terminal
(histidine)6 tag [64]. Three days after infection, tissue culture
supernatant was harvested and gEt protein was purified through a
Talon metal affinity column (Clontech, Mountain View, CA).
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PBS buffer alone, 0.5 mg/ml of EZ-Link Sulfo-NHS-Biotin in
PBS (pH 8.0) (Pierce, Rockford, IL) was added to the resin and
incubated for 30 min at 25uC followed by three washes with cold
PBS. The biotinylated protein was then eluted with 250 mM
imidazole and dialyzed overnight in PBS.
ELISA assay to detect gE-Fc fusion proteins and rIDE
interactions
gE-Fc and control (vaccinia P7.5 and EBV BZLF2) Fc fusion
proteins were described previously [3]. Serial dilutions of Fc fusion
proteins were coated onto an ELISA plate at 4uC overnight. After
washing with PBS containing 0.05% Tween-20, anti-human Fc-
horseradish peroxidase was added (Pierce, Rockford, IL). The
amount of Fc fusion protein, designated as specific Fc units, was
measured spectrophotometrically at OD450 nm after adding
substrate-chromogen TMB (Dakocytomation, Carpinteria, CA).
rIDE was coated onto an ELISA plate at 500 ng/well at 4uC
overnight. After washing with PBS containing 0.05% Tween-20
and blocking with 5% BSA, Fc fusion proteins were added at the
same specific units (see above) at room temperature for 45 min to
allow binding, followed by addition of anti-human Fc-horse radish
peroxidase and TMB substrate.
Insulin degradation assay
rIDE was purified from baculovirus-infected cells using an anti-
HA affinity column and eluted with HA peptide [3]. IDE from rat
liver was purified by multiple chromatographic steps as described
previously [13]. Recombinant human IDE containing hexahisti-
dine and FLAG epitopes fused to the amino terminus of IDE was
expressed in HEK-293T cells and purified using cobalt affinity
chromatography [14]. Protein concentrations were determined
using the BCA protein assay kit (Pierce, Rockford, IL). For
degradation assays, samples of IDE were incubated with
125I-
labeled insulin for 15 min at 37uC. IDE preparations were each
diluted to attain an equal level of insulin degradation. Samples
were resolved by reverse-phase chromatography using a C8
column as described previously [65]. Fractions were collected and
the radioactivity was counted. The degree of insulin degradation
was defined as the proportion of remaining intact insulin to total
recovered radioactivity. The pmoles of insulin degraded in each
sample was calculated from the specific activity of the
125I-labeled
insulin.
Myristylation assay of gE
MeWo cells were infected with cell-associated VZV ROka or
ROka68D32-71 for 24 hr, labeled with
3H-9,10 myristic acid
(167 mCi/ml) (Perkin-Elmer, Waltham, MA) for 18 hr, and lysed in
RIPA buffer. VZV gE was immunoprecipitated with gE monoclo-
nal antibody (Chemicon, Temecula, CA) and protein A-Sepharose
beads (Sigma-Aldrich, St. Louis, MO), and separated on a 4–20%
SDS-PAGE gel (Invitrogen, Carlsbad, CA). The gel was incubated
with
3[H]-ENHANCE (Perkin-Elmer, Waltham, MA) according to
manufacturer’s instructions before autoradiography.
Immuno-electron microscopy
Human melanoma cells were seeded on Thermanox coverslips
(Nalge Nunc International, Rochester, NY) and infected with cell-
associated VZV ROka68D32-71 or parental virus (ROka). When
similar CPE was noted, cells were fixed with 2% paraformalde-
hyde (Electron Microscopy Sciences, Hatfield, PA) on ice for
20 min. The coverslips were then incubated with 5% milk, and
stained with anti-gE antibody (Millipore, Billerica, MA) and
FluoroNanogold conjugated-anti-mouse Fab’-AlexaFluor488 (Na-
noprobes, Yaphank, NY) followed by a final fixation with 4%
paraformaldehyde, 2.5% glutaraldehyde in 0.1 M sodium caco-
dylate buffer overnight at 4uC. Samples were washed three times
with distilled water followed by 0.01 M sodium citrate and silver
enhanced for 4 min with HQ silver reagents (Nanoprobes,
Yaphank, NY). Samples were post-fixed with 1.0% osmium
tetroxide/0.8% potassium ferrocyanide in 0.1 M sodium cacodyl-
ate, dehydrated with a graded ethanol series, and embedded in
Spurr’s resin. Thin sections were cut with an RMC MT-7000
ultramicrotome (Ventana, Tucson, AZ), and stained with 1%
uranyl acetate prior to viewing at 80 kV on a Hitachi H-7500
transmission electron microscope (Hitachi, Tokyo, Japan). Digital
images were acquired with a Hammamatsu XR-100 bottom
mount digital camera system (Advanced Microscopy Techniques,
Danvers, MA) and processed using Adobe Photoshop v. 7 (Adobe
Systems Inc, San Jose, CA).
Real-time PCR to detect VZV internalization
VZV internalization was assayed by modifying a previous
protocol used to determine internalization of Kaposi’s sarcoma-
associated herpesvirus [66]. Cell-free VZV preparations, filtered
through a 5.0 mM non-pyrogenic filter (Pall Corporation, Corn-
wall, UK), were added to MeWo cells seeded in 6-well plates in
SPGC buffer on ice for 60 min to allow binding. Cell entry was
initiated by raising the incubation temperature to 37uC for the
indicated time. Extracellular virus was removed by treating the
cells with 300 mg/ml heparin in PBS on ice for 20 min, washing
with PBS, inactivating virus with low pH Na-Citrate buffer
(40 mM sodium citrate, 10 mM KCl; 135 mM NaCl, pH 3.6) at
room temperature for 2 min [67], and washing with PBS.
Extracellular VZV viral DNA was removed by incubating the
cells with 100 mg/ml proteinase K in HBSS buffer (Invitrogen,
Carlsbad, CA) with 1 mM CaCl2 at room temperature for 5 min,
washing with PBS, and adding 4 units of DNase I per sample at
room temperature for 10 min (Roche Applied Science, Indiana-
polis, IN). Intracellular VZV viral DNA was then extracted
together with cellular genomic DNA using a DNeasy blood &
tissue kit (Qiagen, Valencia, CA) following the manufacturer’s
protocol. The copy number of intracellular VZV genomic DNA
was determined by real-time PCR using primers and a probe
targeting VZV ORF62 as described previously [68]. Serial
dilutions of plasmid pCMV62 were used to generate a standard
curve, and copy numbers of VZV genomic DNA were normalized
using the copy number of human RNaseP DNA amplified from
the same samples. The effectiveness of heparin treatment and acid
inactivation to remove un-internalized virus, and proteinase K
followed by DNase I digestion to remove extracellular viral DNA
was verified by quantitative PCR with DNA extracted from the
virus-bound cells (virus binding on ice for 60 minutes without
shifting to 37uC).
Limited proteolysis to detect conformational changes in
ligand-receptor interactions
Pulse proteolysis [20] of gEt was performed with the following
modifications. Biotinylated gEt protein was incubated with rIDE or
control proteins at room temperature or 37uC for 30 min followed
byaddingequalvolume of6 Murea for18 hratroomtemperature.
Thermolysin diluted in buffer (2.5 M NaCl, 10 mM CaCl2) was
added at 0.2 mg/ml at room temperature for 30 sec. The digestion
was then terminated by adding 0.5 M EDTA and samples were
boiled in SDS-PAGE gel loading buffer with 2.5% 2-mercaptoeth-
anol and separated by electrophoresis. Protein fragments were
detected by streptavidin conjugated-horse radish peroxidase.
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A membrane fusion assay using a b-galactosidase reporter was
adapted from Feng et. al. [69]. The pG1N-T7-b-gal plasmid
encodes b-galactosidase under the T7 promoter and was a gift
from Ed Berger (NIAID, NIH, Bethesda, MD) [70]. Plasmid
pAR3126 encodes T7 polymerase driven by an SV40 early
promoter [71] and was kindly supplied by William Studier
(Brookhaven National Laboratory, Upton, New York). MeWo
cells stably expressing T7 polymerase were generated by co-
transfecting pAR3126 and pCI-Neo (Promega, Madison, WI)
followed by neomycin selection at 1.0 mg/ml. VZV ROka or
ROka68D32-71 was propagated and titrated to equivalent PFU
(plaque forming units) in the MeWo cells expressing T7
polymerase and served as effecter cells. VZV permissive HeLa
cells were transfected with pG1N-T7-b-gal for 24 hr and served as
target cells. Effecter cells (VZV-infected MeWo cells expressing T7
polymerase) were mixed with target cells (HeLa cells with the b–
galactosidase gene driven by the T7 promoter) for 20-24 hrs at
37uC. Cells were then lysed in PBS containing 0.01% NP40, and
b- galactosidase expression resulting from fusion of effecter with
target cells was measured by incubating the lysate with
chlorophenol red-b-D-galactopyranoside (Roche Applied Science,
Indianapolis, IN) and performing spectrophotometry at
OD570 nm.
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